SPECT/CT imaging revealed apparent accumulation of the radiotracer in the MDA-MB-453 tumours (ROI = 3.58 ± 0.01%ID/g at 30 min post-injection), whereas HER2-negative MDA-MB-231 tumours presented considerably lower signals (ROI = 0.73 ± 0.22%ID/g at 30 min post-injection). Here, ERBB2 is linked to neoplasm.